- Home
- ETY vs CPRX Comparison
ETY vs CPRX Comparison
Compare ETY & CPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ETY | CPRX |
|---|---|---|
| Founded | N/A | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 3.0B |
| IPO Year | 2005 | 2006 |
Fundamental Metrics
Financial Performance| Metric | ETY | CPRX |
|---|---|---|
| Price | $14.38 | $23.60 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $35.00 |
| AVG Volume (30 Days) | 206.1K | ★ 1.1M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 28.24 |
| EPS | N/A | ★ 1.68 |
| Revenue | N/A | ★ $119,072,803.00 |
| Revenue This Year | N/A | $8.00 |
| Revenue Next Year | N/A | $9.77 |
| P/E Ratio | ★ N/A | $14.53 |
| Revenue Growth | N/A | ★ 16.39 |
| 52 Week Low | $11.82 | $19.05 |
| 52 Week High | $16.03 | $26.56 |
Technical Indicators
Market Signals| Indicator | ETY | CPRX |
|---|---|---|
| Relative Strength Index (RSI) | 30.65 | 44.50 |
| Support Level | N/A | $22.46 |
| Resistance Level | $15.71 | $24.86 |
| Average True Range (ATR) | 0.18 | 0.99 |
| MACD | -0.04 | -0.04 |
| Stochastic Oscillator | 7.59 | 40.82 |
Price Performance
Historical ComparisonAbout ETY Eaton Vance Tax-Managed Diversified Equity Income Fund of Beneficial Interest
Eaton Vance Tax-mgd Dvsf Eq Inc Fd is a diversified, closed-end management investment company. Its primary investment objective is to provide current income and gains. The secondary objective of the fund is capital appreciation. Its portfolio of investments consists of capital markets, banks, internet and direct marketing retail, biotechnology, media, oil, gas, and consumable fuels, and other sectors.
About CPRX Catalyst Pharmaceuticals Inc.
Catalyst Pharmaceuticals Inc is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. The Company sells three commercial stage drug products, FIRDAPSE (amifampridine), AGAMREE (vamorolone), and FYCOMPA (perampanel). The Company is currently seeking to further expand its product portfolio, with a focus on acquiring the rights to immediately and near-term accretive assets to treat rare (orphan) diseases across therapeutic areas, including clinical-stage opportunities with established proof of concept.